Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth

Digestion

Volumn 71, Issue 3, 2005, Pages 131-140

  Lankat Buttgereit, Brigitte ^a   Hörsch, Dieter ^a   Barth, Peter ^a   Arnold, Rudolf ^a   Blöcker, Silke ^a   Göke, Rüdiger ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Apoptosis; c Kit; Carcinoid syndrome; Endocrine tumor; Gastrinoma; Imatinib (Gleevec ); Insulinoma

Indexed keywords

DOXORUBICIN; FLUOROURACIL; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TELOMERASE; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOID; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG SENSITIVITY; ENDOCRINE TUMOR; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GASTRINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; NEUROENDOCRINE TUMOR; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR GROWTH; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMORS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 21344437299     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084647     Document Type: Article

References (35)

1. Hunter T: Oncoprotein networks. Cell 1997; 88:333-346.
2. Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185.
3. Vlahovic G, Crawford J: Activation of tyrosine kinases in cancer. Oncologist 2003;8:531-538.
4. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997;90:4947-4952.
5. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
6. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 2001;411:355-365.
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
8. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
9. Toyota M, Hinoda Y, Takaoka A, Makiguchi Y, Takahashi T, Itoh F, Imai K, Yachi A: Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol 1993;14: 295-302.
10. Hines SJ, Organ C, Kornstein MJ, Krystal GW: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995;6:769-779.
11. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, Ariyoshi Y, Takahashi T: Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991;51:2416-2419.
12. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
13. Tian Q, Frierson HF, Krystal GW, Moskaluk CA: Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:1643-1647.
14. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-10564.
15. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker BJ, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
16. Krystal GW, Honsawek S, Litz J, Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-3326.
17. Öberg K: Endocrine tumors of the gastrointestinal tract: Systemic treatment. Anticancer Drugs 1994;5:503-519.
18. Öberg K: Carcinoid tumors: Molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002;14:38-45.
19. Takaki R, Ono J, Nakamura M, Yokogawa Y, Kumae S, Hiraoka T, Yamaguchi K, Hamaguchi K, Uchida S: Isolation of glucagon-secreting cell lines by cloning insulinoma cells. In Vitro Cell Dev Biol 1986;22(3 Pt 1):120-126.
20. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62:6304-6311.
21. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diammine-dichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51: 4575-4580.
22. Fan Z, Masui H, Atlas I, Mendelsohn J: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993;53: 4322-4328.
23. Trümper A, Trümper K, Trusheim H, Arnold R, Göke B, Hörsch D: Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001;15:1559-1570.
24. Chang JY: Telomerase: A potential molecular marker and therapeutic target for cancer. J Surg Oncol 2004;87:1-3.
25. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787-791.
26. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ: KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78:1633-1636.
27. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
28. DeMatteo RP: The GIST of targeted cancer therapy: A tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 2002;9: 831-839.
29. Cataldi M, Gaudino A, Lariccia V, Russo M, Amoroso S, di Renzo G, Annunziato L: Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism. J Pharmacol Exp Ther 2004;309:208-215.
30. Zhou L, An N, Haydon RC, Zhou Q, Cheng H, Peng Y, Jiang W, Luu HH, Vanichakarn P, Szatkowski JP, Park JY, Breyer B, He TC: Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 2003;193:161-170.
31. Okada M, Adachi S, Imai T, Watanabe K, Toyokuni SY, Ueno M, Zervos AS, Kroemer G, Nakahata T: A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: Caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 2004;103:2299-2307.
32. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-959.
33. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR: Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999;96: 14276-14281.
34. Carr K, Yao JC, Rashid A, Yeung SC, Szklaruk J, Baker J, Vauthey JN, Curley S, Ellis L, Ajani JA: A phase II trial of imatinib in patients with advanced carcinoid tumor. J Clin Oncol 2004; 22:344.
35. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-2878.